Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.558
+0.056 (11.16%)
At close: Dec 20, 2024, 4:00 PM
0.541
-0.017 (-3.01%)
After-hours: Dec 20, 2024, 7:59 PM EST
Lineage Cell Therapeutics Employees
As of December 31, 2023, Lineage Cell Therapeutics had 75 total employees, including 68 full-time and 7 part-time employees. The number of employees decreased by 3 or -3.85% compared to the previous year.
Employees
75
Change (1Y)
-3
Growth (1Y)
-3.85%
Revenue / Employee
$116,253
Profits / Employee
-$268,147
Market Cap
122.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Editas Medicine | 265 |
TELA Bio | 227 |
Zomedica | 144 |
Tenaya Therapeutics | 140 |
Allakos | 131 |
TriSalus Life Sciences | 112 |
Cabaletta Bio | 103 |
Milestone Pharmaceuticals | 47 |
LCTX News
- 4 weeks ago - Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering - Business Wire
- 4 weeks ago - Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering - Business Wire
- 5 weeks ago - Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit - Business Wire
- 3 months ago - OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium - Business Wire
- 3 months ago - Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop - Business Wire